Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme

Expert Review of Anticancer Therapy

Volumn 6, Issue 9, 2006, Pages 1313-1322

  Panner, Amith ^a   Parsa, Andrew T ^a   Pieper, Russell O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; AP23573; Apoptosis; CCI 779; Glioma; mTOR; PTEN; RAD001; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AP 23573; CAMPTOTHECIN; CISPLATIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TEMSIROLIMUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; GLIOBLASTOMA; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; SIROLIMUS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOR SERINE-THREONINE KINASES;

EID: 33750071985     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.1313     Document Type: Review

References (58)

1. Vivianco I, Sawyers CL. The phosphophatidylinositol 3-kinase/AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
2. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 4, 648-657 (2002).
3. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10, 151-162 (2002).
4. Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4, 658-665 (2002).
5. Garami A, Zwartkruis FJ, Nobukuni T et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC 1 and 2. Mol. Cell 11, 1457-1466 (2003).
6. Saucedo LJ, Goa X, Chiarelli DA, Li L, Pan D, Edgar BA. Rheb promotes cell growth as a component of the insulin/mTOR signaling network. Nat. Cell Biol. 5, 566-571 (2003).
7. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumor suppressor proteins. Nat. Cell Biol. 5, 578-581 (2003).
8. Im E, von Lintig FC, Chen J et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21. 6356-6365 (2002).
9. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb promotes tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32493-32496 (2003).
10. Fingar DC, Richardson AR, Tee L, Cheatham C, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol. 24, 200-216 (2004).
11. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171 (2004).
12. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4E-BP1/eIF4E. Genes Dev. 16, 1472-1478 (2002).
13. Gingras AC, Raught B, Sonenberg N. Regulation of translation inhibition by FRAP/mTOR. Genes Dev. 15, 807-826 (2001).
14. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediated TOR action. Cell 110, 177-189 (2002).
15. Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175 (2002).
16. Abraham RT. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 111, 9-12 (2002).
17. Radimerski T, Montagne J, Rintleen F et al. dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat. Cell Biol. 4, 251-255 (2002).
18. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signaling. Biochem. Soc. Trans. 31, 573-578 (2003).
19. Stolovich M, Tang E, Hornstein G et al. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phophatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell Biol. 22, 8101-8113 (2002).
20. Janus A, Robak T, Smolewski P. The mammalian target of rapamycin (mTOR) kinase pathway: Its role in tumourgenesis and targeted antitumor therapy. Cell Mol. Biol. Lett. 10. 479-498 (2005).
21. Jin W, Wu L, Llang K, Llu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br. J. Cancer 89, 185-191 (2003).
22. Gottschalk AR, Basila D, Wong M et al. p27 Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res. 61, 2105-2111 (2001).
23. Schlieman MG, Gahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 89, 2110-2115 (2003).
24. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and independent pathways. Cancer Cell 4, 147-184 (2003).
25. De Benedetti A, Graff JR. eIF4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199 (2004).
26. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr. Relat. Cancer 8, 237-248 (2001)
27. Ward SG. Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3, 426-434 (2003).
28. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194 (2005).
29. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2, 169-177 (2003).
30. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16, 564-575 (2004).
31. Law M, Forrester E, Chytil A et al. Rapamycin disrupts cyclin/ cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res. 66, 1070-1080 (2006).
32. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85 (2003).
33. Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
34. Blagoskonny MV, Darzynkiewicz Z. Four birds with one stone: RAPA as potential anticancer therapy. Cancer Biol. Ther. 1, 359-361 (2002).
35. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178-194 (2005).
36. Galanis E, Buckner JC, Maurer JI et al. Phase II trial of Temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol. 23, 5294-5304 (2005).
37. Forouzesh B, Buckner JC, Marks AJ et al. Phase 1, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies: 2002 EORTC-NCI-AACR Symposium on Molecular targets and Cancer Therapeutics. Eur. J. Cancer 54, 168 (2002).
38. O'Reilly T, Vaxelaire J, Muller M et al. In vivo activity or RAD 001, an orally active rapamycin derivative, in experimental tumor models. Proc. Am. Assoc. Cancer Res. (2002) (Abstract 359).
39. Clackson T, Metcalf III CA, Rozamus LW et al. Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc. Am. Assoc. Cancer Res. 43, 95 (2002) (Abstract LB).
40. Pacey S, Rea D, Steven N, Brock C et al. Results of Phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E. Rad001) and Gemcitabine (GEM) in patients (pts) with advanced cancers: 2004 ASCO Meeting. J. Clin Oncol. 22, 3120 (2004).
41. Dudkin L, Dilling MB, Cheshire PJ et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7, 1758-1764 (2001).
42. Geoerger B, Kerr K, Tang CB et al Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61, 1527-1532 (2001).
43. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin. Ann. Oncol. 16, 525-537 (2005).
44. Rivera V, Tang H, Metcalf C et al. Anti-proliferative activity or the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc. Am. Assoc. Cancer Res. 45, 3887 (2004).
45. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differentiation 10, 66-75 (2003).
46. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348 (2003).
47. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Path. Oncol. Res. 7, 95-106 (2001).
48. Xiao C, Yang BF, Asadi N, Beguinot F. Hao C. Tumor necrosis factor-related apoptosis-inducing ligand induces death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J. Biol. Chem. 277, 25020-25025 (2001).
49. Nam SY, Jung GA, Hur GC et al. Upregulation of FLIPs by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 94, 1066-1073 (2003).
50. Varfolomeev E, Maecker H, Sharp D et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis-factor related apoptosis-inducing ligand. J. Biol. Chem. 280, 40599-40608 (2005).
51. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16, 33-45 (2001).
52. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/ TRAIL - or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8, 807-815 (2002).
53. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25. 8809-8823 (2005).
54. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat. Immunol. 3, 221-227 (2002).
55. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem. 276, 37879-37866 (2001).
56. Eshleman JS, Carlson BL, Mladek AC. Kastner BD, Shide K, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 62, 7291-7297 (2002).
57. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5, 876-885 (2005).
58. Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10, 7031-7042 (2004).